Thank you, Mr. Chair.
Dr. Patel, I have two, hopefully, fairly brief questions, because I also have a couple of questions for Dr. Ghosh.
You talked about the conundrum of supervised consumption really being designed around longer-acting drugs, principally heroin. You mentioned that people often don't even have time to get into the facility, because of the use of short-acting drugs.
Can you talk a bit about that mismatch, and what we need to do? Should we be actually putting more resources into safe consumption to make it that much more accessible, or is there a bit of a mismatch between the short-acting drugs and supervised consumption facilities?